1070 Design and Implementation of Data Quality Controls in the EQ-DAPHNIE Study: Insights from the Pilot Phase and 15-Country Analysis Fatima Al Sayah 1 , Hilary Short 1 , Juan M
Other notable citations include 211.165(a), (b), (d), or (e) related to testing and release for distribution, which is cited in 34 letters, and 211.160 for laboratory controls, which is cited in 33 letters
The Bottom Line Ipamorelin is a pentapeptide GH secretagogue that activates the GHS-R1a (ghrelin) receptor to release growth hormone without stimulating cortisol, ACTH, or prolactin, a selectivity profile documented at doses 200-fold above its effective GH-releasing dose
21 Advanced neurologic symptoms may not respond to replacement
Beyond those standing concerns, in a press announcement dated March 3, 2026 (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products